Surgery Removing Surrounding Fat Tissue in Crohn's Disease Patients on Biotherapy
Tests a wider bowel surgery in adults with ileocolic Crohn's disease on biotherapy.
Key facts
- Who runs it
- Centre Hospitalier Universitaire de Nīmes
- Where
- Montpellier and Nîmes, FranceSee the 2 sites
- Trial code
- Registry title
- Safety of Mesentery-embedding Surgery in Patients With Ileocolic Crohn's Disease on Biotherapy
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 15 Sept 2025
- Expected to end
- Mar 2028
- Type of study
- Interventional
- Treatments tested
- ileocolic resection with extended mesenteric resection
- Record updated
- 16 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Crohn's disease who are on biotherapy and have had an ileocolic resection (surgery on the end of the small bowel and the colon).
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Crohn's disease proven by tissue examination (histology), with the disease site reachable by endoscopy for follow-up
- Earlier treatment
- Currently on biotherapy: infliximab, adalimumab, vedolizumab, ustkinumab, or another biotherapy (for example risankizumab). Has had an ileocolic resection (first or repeat operation).
Main reasons for not taking part
- Taking an interventional study drug or procedure at the same time as another study
- Medical treatment other than biotherapy
- Contraindication to surgery, such as major heart and blood vessel disease
- Pregnant, breast-feeding or women giving birth
- Under legal protection (safeguard of justice or state guardianship)
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- The patient must have given their free and informed consent and signed the consent form
- The patient must be a member or beneficiary of a health insurance plan
- Patient with histologically proven Crohn's disease
- Patient who has undergone ileocolic resection and whose disease site is accessible to endoscopic follow-up (first or repeat operation)
- Patient on anti-TNF α: infliximab or adalimumab (ECCO 2014 recommendation), vedolizumab, ustkinumab, or other biotherapy (e.g. risankizumab)
- Patient able to understand, write and read French
Who cannot take part
- Contraindication to surgery, such as major cardiovascular comorbidities
- The patient is participating in an interventional study
- The patient is under safeguard of justice or state guardianship
- Medical treatment other than biotherapies including anti-TNF α (infliximab or adalimumab), vedolizumab, ustkinumab, risankinumab
- Pregnant, breast-feeding or parturient women
Where in France
- CHU de Montpellier Hôpital St EloiMontpellier, FranceContact: Thomas BARDOLTaking people
- CHU de NîmesNîmes, FranceContact: Anissa MEGZARITaking people
About the trial
What the trial wants to find out
60% of patients with Crohn's disease will undergo surgery during their lifetime and without recurrence prevention treatment, 80% of patients will have an endoscopic recurrence within 1 year of surgery. This procedure is performed as close as possible to the gastrointestinal tract, but remaining mesenteric disease is a risk factor for recurrence. Mesentery resection has encouraging results on recurrence requiring reoperation, with a reduction of over 30% in recurrences compared with the standard technique. The study authors wish to evaluate the safety of ileocolic resection surgery involving the mesentery in patients with Crohn's disease treated with biotherapy.
Read full original descriptionShow less
The study hypothesis is that mesentery surgery is no more risky than conventional (gold standard) surgery, and reduces the 6-month endoscopic recurrence rate in patients with ileocolic Crohn's disease on biotherapy requiring ileocolic resection.
The group in the trial
- Patient with Crohn DiseaseTreatment being tested
Treatment: ileocolic resection with extended mesenteric resection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Etude Prospective Exploratoire Pilote de sécurité, d'Une Chirurgie Emportant le mésentère Chez Les Patients Porteurs d'Une Maladie de Crohn Avec Atteinte iléo-colique Sous biothérapie
- Plain-language title
- Surgery Removing Surrounding Fat Tissue in Crohn's Disease Patients on BiotherapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 16 March 2026